Loading...
Loading...
Contributors:
Dataset URI:
10.1021/acsinfecdis.6c00433.s007Antibiotic resistance is a critical public health concern, with approximately 2.8 million Americans infected with antibiotic-resistant bacteria annually and over 35,000 deaths in the United States alone. Of particular concern are Enterobacterales that express metallo-β-lactamases (MBLs), bacteria that cause nosocomial infections and exhibit resistance to most β-lactam drugs. The zinc-containing active sites of MBLs differ from those of serine β-lactamases, making current clinical inhibitors ineffective. No FDA-approved MBL inhibitors exist, leaving a critical gap in therapeutics for MBL-expressing Enterobacterales infections. Herein, we biochemically and spectroscopically demonstrate irreversible inhibition of the metallo-β-lactamase NDM-1 by a subset of cobalt(III) Schiff base complexes (Co(III)-sb). Crystallography and 59Co NMR experiments show that inactivation efficiency is dependent on axial and equatorial ligand identity. While Co(III)-sb exhibits NDM-1 inhibition, chemical modification is required to enable complexes to cross the Gram-negative envelope. These findings establish Co(III)-sb complexes as a novel scaffold for the development of MBL inhibitors.
Keyword(s):
000 deaths; 59; approximately 2; Biochemistry; Biological Sciences not elsewhere classified.
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)